What’s new on the horizon for lipoprotein(a) therapies?
Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
For expert analysis and insights
17th Virtual Closed Scientific Expert Meeting of the Editorial Board
What's new in lipoprotein(a) therapeutics?
Dr Michael Koren overviews the latest data with the siRNA olpasiran, including the OCEAN(a) trial.
Related content:
What’s new on the horizon for lipoprotein(a) therapies?
Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”
View all presentations from the 17th Closed Scientific Expert Meeting »
Lipoprotein(a) and atrial fibrillation – Is there a link?
Profs. John Chapman and Henry Ginsberg discuss new data implicating Lp(a) as a potential causal mediator of atrial fibrillation.
Related reports:
Updated lipoprotein(a) consensus paper
Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”
Does PCSK9 inhibition reduce the risk of venous thromboembolism?